Literature DB >> 9839302

A comprehensive assessment of the cost of multiple sclerosis in the United States.

K Whetten-Goldstein1, F A Sloan, L B Goldstein, E D Kulas.   

Abstract

Comprehensive data on the costs of multiple sclerosis is sparse. We conducted a survey of 606 persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings. Compensation of such cost in the form of health insurance, income support, and other subsidies was measured. Survey data and data from several secondary sources was used to measure costs incurred by comparable persons without MS. Based on the 1994 data, the annual cost of MS was estimated at over $34,000 per person, translating into a conservative estimate of national annual cost of $6.8 billion, and a total lifetime cost per case of $2.2 million. Major components of cost were earnings loss and informal care. Virtually all persons with MS had health insurance, mostly Medicare/Medicaid. Health insurance covered 51 per cent of costs for services, excluding informal care. On average, compensation for earnings loss was 27 per cent. MS is very costly to the individual, health care system, and society. Much of the cost (57 per cent) is in the form of burdens other than personal health care, including earnings loss, equipment and alternations, and formal and informal care. These costs often are not calculated.

Entities:  

Mesh:

Year:  1998        PMID: 9839302     DOI: 10.1177/135245859800400504

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  44 in total

Review 1.  Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Authors:  Jürg Kesselring
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  The impact of the financial costs of multiple sclerosis on quality of life.

Authors:  Margaret A De Judicibus; Marita P McCabe
Journal:  Int J Behav Med       Date:  2007

3.  Funding of research on headache disorders by the National Institutes of Health.

Authors:  Todd J Schwedt; Robert E Shapiro
Journal:  Headache       Date:  2009-02       Impact factor: 5.887

4.  Health insurance affects the use of disease-modifying therapy in multiple sclerosis.

Authors:  Guoqiao Wang; Ruth Ann Marrie; Amber R Salter; Robert Fox; Stacey S Cofield; Tuula Tyry; Gary R Cutter
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

5.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

Review 8.  Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.

Authors:  Daniel M Hartung
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-05       Impact factor: 5.081

9.  Internet portal use in an academic multiple sclerosis center.

Authors:  A Scott Nielsen; John D Halamka; R Philip Kinkel
Journal:  J Am Med Inform Assoc       Date:  2011-05-12       Impact factor: 4.497

10.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.